Russians love Putin's dustup with the West. But they've stopped spending money
Why rival discounters are vying for control of Family Dollar Stores
Twitter's head of product, Daniel Graf, must make the service more user-friendly without offending hard-core fans
Yale's Robert Shiller is sending up warning flares. It may be best to ignore him
To minimize flood chaos, turn the hospital upside down
Bayer is marketing Berocca as performance drink, but Australians know what it's really for
After years of effort, top B-schools still enroll only about 40 percent female MBAs
Advice for a small bed-and-breakfast trying to get on the map for international tourists
Founder: Dr. Mark Pruzanski
VC Investment over the last four quarters: $25 million
Founded in 2002, the 25-employee biopharmaceutical company is in the process of developing therapeutic treatment of chronic fibrotic and metabolic diseases. Despite the downturn, the company raised significant funding this year. Sticking to a tight budget, Intercept expects to have enough cash resources to fund its operations until 2010.
Key to startup success: "Be persistent. Intercept was founded just before the last major downturn for biotech, which lasted through 2003 and venture capital completely dried up for new early-stage startups. [We] remained passionately dedicated to the company and persisted even though it took more than a year to secure financing."